Evidence-based non-skeletal actions of vitamin D

Patricia Muszkat\(^1\), Marília Brasilio Rodrigues Camargo\(^1\), Luiz Henrique Maciel Griz\(^2\), Marise Lazaretti-Castro\(^1\)

**SUMMARY**

Vitamin D is a major regulator of mineral homeostasis through its action in the kidney, intestine, bone and parathyroid glands. On these tissues, its active form, calcitriol, acts by binding to a specific nuclear receptor that belongs to the steroid/thyroid hormone receptor family. This receptor, however, has also been identified in several additional human tissues. So, apart from its traditional actions related to calcium, vitamin D and its synthetic analogs are being increasingly recognized for their anti-proliferative, pro-differentiative and immunomodulatory activities.

Low levels of vitamin D have been linked to many chronic diseases. Decreased muscle function and increased fall risk in elderly people; prostate, breast and colorectal cancers; diabetes mellitus; and other health problems have been associated to low circulating levels of 25-hydroxyvitamin D.

This paper presents an overview of the available scientific evidence for the non-calcemic actions of vitamin D in humans.

**Keywords**

Vitamin D; metabolism; deficiency; cancer; muscle strength; calcium

---

**INTRODUCTION**

Vitamin D\(_3\) is truly a prohormone rather than a vitamin. It is produced in the skin through ultraviolet irradiation of 7-dehydrocholesterol (Figure 1). Some nutrients like fatty fish, eggs and dairy products also contain vitamin D\(_3\), but they are not consumed as frequently as necessary for an essential dietary factor. Our main source of vitamin D\(_3\) is endogenous production (1). The adequate requirement of vitamin D may be achieved if the exposition of the skin with solar ultraviolet radiation occurs in a regular and safe manner. This correlation between sun exposure and plasma concentrations of 25-hydroxyvitamin D (25OHD) becomes
Non-skeletal actions of vitamin D

apparent when evaluated over the months of the year. There is a clear seasonal variation in these levels in the elderly and even in young people (2,3). In an elderly population living in São Paulo, Brazil, 25OHD levels after summer are twice as high as those observed after winter, at 67.2 nmol/L and 29.1 nmol/L, respectively (2). In young people living in this same city we also found a seasonal variation but of lower magnitude; their summer 25OHD levels were approximately 30% higher than winter concentrations (3).

Thanks to migratory movements in the world population and the behavioral changes witnessed in the last century, body sun expositions have become rare, and vitamin D deficiency has reached epidemic rates worldwide (4). Even in sunny countries such as Brazil data are impressive: 71.2% of the institutionalized and 55.8% of the free-living elderly from the city of São Paulo (23°S) had very low levels of 25OHD (< 50 nmol/L and < 20 ng/mL), with almost the same proportion of secondary hyperparathyroidism, 61.7% and 54.0%, respectively (Figure 2) (5). For practical reasons we should keep in mind that an exposure time of 10 minutes three times per week of unprotected head and arms would be adequate to prevent vitamin D deficiency (4,6,7).

A meta-analysis of randomized, controlled trials published in 2007 reviewed the association between vitamin D supplementation and total mortality. The mean daily dose of vitamin D supplements ranged from 400 IU to 833 IU. The authors concluded that the intake of ordinary doses of vitamin D supplements seems to be associated with decreases in total mortality. The relationship between baseline vitamin D status, dose of vitamin D supplements and total mortality rates remains to be investigated (8).

VITAMIN D METABOLISM

Vitamin D is denominated a secosteroid because one of the rings of its cyclopentanoperhydrophenanthrene structure has a broken carbon-carbon bond (Figure 1). Vitamin D₃ undergoes two hydroxylation reactions, a hepatic 25-hydroxylation and a renal 1-α-hydroxylation, to produce the active hormone 1α,25 dihydroxyvitamin D₃ [1,25(OH)₂D₃]. The steroid hormone 1,25(OH)₂D₃ interacts with a single vitamin D receptor in the cell nucleus to exert its biological functions. It is well known that the active metabolite 1,25(OH)₂D₃ plays an important role in bone mineral metabolism and health, however, 1,25(OH)₂D₃ has a wide range of non-calcemic actions that are also useful for promoting optimal health (7,9,10).

Vitamin D receptor (VDR) is a phosphoprotein member of the nuclear receptor superfamily that functions as a ligand-dependent transcription factor. VDR binds as a heterodimer with retinoid X receptor (RXR) to hexameric repeats, characterized as vitamin D responsive elements present in the regulatory region of many target genes such as osteocalcin, osteopontin, calbindin-D28K, calbindin-D9K, TGF-β2 and vitamin D 24-hydroxylase. Many factors such as glucocorticoids, estrogens, retinoids, cell proliferation rate and transformation can modulate VDR levels (11). The molecular cloning of VDR and the identification of its widespread expression in human tissues led researchers to suspect that the vitamin D endocrine system has additional physiological functions beyond calcium homeostasis. Vitamin D and VDR have been shown to play important roles in the immune, cardiovascular and reproductive systems and in hair growth. The few cells or tissues that have low or absent VDR expression include red blood cells, mature striated muscle cells and some differentiated brain cells, such as Purkinje cells of the cerebellum (10). An important step in studying the functions of 1,25(OH)₂D₃ was the generation of VDR- and 1α-hydroxylase-null mice (12). Table 1 summarizes features of nontraditional 1,25(OH)₂D₃ target tissues in VDR-null mice.

![Figure 1. Photobiosynthesis of vitamin D₃ in skin.](image-url)
Table 1. Non-classical 1α,25-dihydroxyvitamin D₃ target tissues in VDR-null mice models

<table>
<thead>
<tr>
<th>Tissue</th>
<th>Feature</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin</td>
<td>Alopecia</td>
</tr>
<tr>
<td></td>
<td>Abnormal hair cycling</td>
</tr>
<tr>
<td></td>
<td>Anti-proliferative and pro-differentiative effect on keratinocytes</td>
</tr>
<tr>
<td>Muscle</td>
<td>Smaller muscle fibers</td>
</tr>
<tr>
<td></td>
<td>Persistent expression of early markers of myogenic differentiation</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>High renin hypertension</td>
</tr>
<tr>
<td>system</td>
<td>Cardiac hypertrophy</td>
</tr>
<tr>
<td>Immune system</td>
<td>Impaired macrophage function</td>
</tr>
<tr>
<td></td>
<td>Abnormal Th1 macrophage-induced formation</td>
</tr>
<tr>
<td></td>
<td>Increased number of immature dendritic cells</td>
</tr>
<tr>
<td></td>
<td>Predisposition to autoimmune diseases such as type 1 diabetes</td>
</tr>
<tr>
<td></td>
<td>Decreased monocytic differentiation and antibacterial activity of monocytes</td>
</tr>
<tr>
<td>Pancreas β cells</td>
<td>Normal glucose tolerance or mild glucose intolerance</td>
</tr>
<tr>
<td></td>
<td>Is a target tissue with discrepancy between effects of the vitamin D ligand and the VDR itself</td>
</tr>
<tr>
<td>Brain</td>
<td>Abnormal behavior, especially muscle and motor behavior</td>
</tr>
<tr>
<td>Cell proliferation/ Cancer</td>
<td>Hyperproliferation of colonic cells</td>
</tr>
<tr>
<td></td>
<td>Dysregulated growth of alveolar and ductal mammary gland cells</td>
</tr>
<tr>
<td>Reproductive system</td>
<td>Uterine hypoplasia</td>
</tr>
<tr>
<td></td>
<td>Impaired ovarian folliculogenesis</td>
</tr>
<tr>
<td></td>
<td>Male infertility</td>
</tr>
</tbody>
</table>

Based on references 9, 21, 40, 52 and 53.

Figure 2. Concentrations of 25 hydroxyvitamin D (25OHD) and parathyroid hormone (PTH) in three different populations living in the city of Sao Paulo, Brazil (23°S): institutionalized and free-living elderly people, compared to young normal controls (3). The marked boxes define the normal range values for both hormones.

VITAMIN D DEFICIENCY AND NON-SKELETAL DISEASES

Low levels of vitamin D have been linked to many chronic conditions and diseases. Epidemiological findings, genetic studies and clinical trials have been published and have shown strong evidence of this linkage (13,14). A great number of in vitro studies give support to these epidemiological and clinical findings. 1,25(OH)₂D₃ has potent anti-proliferative and pro-differentiative effects in a wide variety of cell types, and its effects have been tested in different types of cancer cells such as prostate, breast, ovarian, colorectal, squamous, and leukemia cells. The variety of target genes identified through these studies reflects the pleiotropic action of 1,25(OH)₂D₃. Common cellular processes targeted by 1,25(OH)₂D₃ in different cancer cell lines include cell-cycle progression, apoptosis, cellular adhesion, oxidative stress, immune function and steroid metabolism (15). This review mentions some of the most important diseases.

Breast cancer

Epidemiologic studies have shown an inverse relationship between sun exposure and a higher incidence of breast cancer (12). A recent meta-analysis of vitamin D and the prevention of breast cancer found a 45% de-
crease in breast cancer risk for those in the highest quartile of circulating 25OHD (60 nmol/L) compared to those with the lowest level. No relationship was found between the level of circulating 1,25(OH)2D3 and breast cancer (16).

VDR is expressed in mammary tissue and breast cancer cells which are potential targets for hormone action. Besides having anti-proliferative properties, vitamin D might also reduce the invasiveness of cancer cells and act as an anti-angiogenesis agent (12). Another piece of evidence that links vitamin D and breast cancer is the fact that the chromosomal region 20q13.2, which contains 24-hydroxylase is amplified in breast cancer (12). Because 24-hydroxylase is involved in 1,25(OH)2D3 degradation, its amplification may lead to decreased serum levels of vitamin D providing an environment conducive for cell growth in the absence of vitamin D-mediated growth control. The exact mechanism underlying the growth inhibitory actions of vitamin D in breast cancer is not clear, but data support that the effect of vitamin D may involve growth arrest at the G0/G1 stage, cell apoptosis or disruption of estrogen and other growth factor-mediated cell survival signals and angiogenesis (12). All of these anti-tumoral features suggest that the properties of vitamin D and VDR could be explored for therapeutic purposes in breast cancer, and different 1,25(OH)2D3 analogs with potent anti-proliferative but lesser hyper-calcemic effects are being developed and tested for clinical use (9).

Prostate cancer

Laboratory in vitro studies have demonstrated that 1,25(OH)2D3 and its synthetic analogs inhibit the proliferation of prostate cancer cell lines (12). Epidemiological studies have also shown that increased exposure to UV light may be protective against prostate cancer, but this finding has been conflicting and requires further investigation to support the association. Polymorphisms of the VDR gene that affect the receptor binding of 1,25(OH)2D3 may modify vitamin D’s biological activity and confer different susceptibility to prostate cancer. In a recent meta-analysis performed by Yin and cols. (19), 36 publications on the association of TaqI, Apal, BsmI, FokI and CDx2 single nucleotide polymorphisms in susceptibility to prostate cancer were identified. The authors suggested that TaqI t and BsmI B alleles were associated with reduced prostate cancer risk among all study populations, whereas the FokI f allele was associated with increased cancer risk among Caucasian populations (19). According to recent evidence, 25OHD may play a role in the regulation of cell proliferation in the prostate. It is mainly acting directly through the VDR, but it may also partially act through its 1alpha-hydroxylation in the prostate. A lack of vitamin D action may also be due to an altered metabolism or vitamin D resistance. Vitamin D resistance might be brought up by several mechanisms, and the local metabolism of hormonal vitamin D seems to play an important role in the development and progression of prostate cancer (20).

Leukemia

1,25(OH)2D3 plays a role in the regulation of the immune system. Cells of the monocyte/macrophage lineage possess receptors for 1,25(OH)2D3 regardless of their activation stage. Further, 1,25(OH)2D3 promotes the differentiation of monocyte precursors towards monocyte/macrophages and enhances monocyte function in antigen presentation. In addition, 1,25(OH)2D3 modulates cytokine production by lymphocytes (21).

Although one of the first described non-classical vitamin D actions was its ability to promote differentiation and block proliferation of murine myeloid leukemia, clinical trials up to this point have failed to obtain good results in clinical management when they use 1,25(OH)2D3 and analogs to treat myelodysplastic syndromes and myeloid leukemia (22).
Non-skeletal actions of vitamin D

Multiple sclerosis
Epidemiological studies have related an increase of multiple sclerosis with increasing geographical latitude. Clinical studies have shown that vitamin D levels are lower among patients with multiple sclerosis. There is also evidence that UV light and calcitriol reduce the symptoms of multiple sclerosis (23).

Type 1 diabetes
Vitamin D deficiency is largely described in diabetes mellitus type 1 (T1DM) patients from different origins (24,25). Vitamin D deficiency has been associated with an increased risk of T1DM. Glycemic control and insulin resistance are improved when vitamin D deficiency is corrected and calcium supplementation is adequate. Studies have also shown an increase in the incidence of T1DM when vitamin D deficiency was present in the first month of life in children (12,23). VDR gene polymorphisms may be associated with the risk of developing T1DM, but reports have been conflicting (26,27). Because 1,25(OH)₂D₃ has very well established in vitro effects on insulin secretion and on immunological response, there are some suggestions that vitamin D deficiency may play a role in the development of type 1 diabetes, although this hypothesis is still to be confirmed.

Type 2 diabetes
Several reports have demonstrated a role of vitamin D in the functional regulation of pancreatic beta cells (28). The identification of receptors for 1,25(OH)₂D₃ (29) and the expression of 1α-hydroxylase enzyme in pancreatic beta cells (30) support a role of vitamin D in pancreatic beta cells. Vitamin D deficiency inhibits pancreatic secretion of insulin (31) and is associated with glucose intolerance (32). Vitamin D is essential for insulin release (33), while vitamin D supplementation restores insulin secretion (34). In peripheral insulin target tissues vitamin D may enhance insulin sensitivity by stimulating the expression of insulin receptors (35).

A large cross-sectional survey showed a significant inverse association between serum 25OHD and diabetes prevalence (36). Recent prospective analysis from an English cohort reported inverse associations between baseline serum 25OHD and future glycemic status and insulin resistance (37), and a Finnish cohort study showed an inverse association between baseline serum 25OHD and the 17-year risk of type 2 diabetes (38). The Nurse’s Health Study (39) demonstrated that women with an average vitamin D daily intake > 800 UI had a 33% lower risk of the incidence of type 2 diabetes compared to an intake < 200 UI.

In spite of these observational data supporting the role of vitamin D in the development of type 2 diabetes, it is unlikely that vitamin D deficiency would be a major cause of this disease. Further cohort studies are required to test the hypothesis that vitamin D deficiency is a cause of diabetes, and we clearly need more evidence that vitamin D supplementation reduces the risk of diabetes.

Muscle function
Several studies have shown that vitamin D metabolites affect muscle cell metabolism through various pathways: by mediating gene transcription, through rapid pathways not involving DNA synthesis and by the allelic variant of the VDR (40). Both in animal models and in humans, a VDR has been found in skeletal muscle cells that specifically binds 1,25(OH)₂D₃. Vitamin D supplementation induces rapid changes in calcium metabolism of the muscle cell that cannot be explained by a slow genetic pathway. Evidence indicates that 1,25(OH)₂D₃, possibly through a vitamin D membrane receptor, acts directly on the muscle cell membrane. Upon 1,25(OH)₂D₃ binding, several interacting second-messenger pathways were activated in the muscle cell, resulting in enhanced calcium uptake. Muscle strength also appears to be influenced by the genotype of the VDR in the muscle cell. Various cases have been described in which prolonged vitamin D deficiency was associated with severe muscle weakness, often leading to a marked disability that improved with vitamin D supplementation. However, few studies have been conducted in which muscle strength was objectively quantified in relation to vitamin D status (10,41-43). In a prospective, double-blind, placebo-controlled, randomized trial with Brazilian institutionalized elderly people we showed that a 6-month vitamin D supplementation significantly improved lower limb muscle strength in the absence of any regular physical exercise practice (Figure 3) (44).

Vitamin D deficiency has also been related to an increase in the incidence of falls. A recent systematic review including eight prospective, double-blind, randomized, controlled studies suggests that vitamin D in doses of 700 to 1000 UI/day may reduce the risk of an elderly person falling by 19%. Doses of supplemental vitamin D less than 700 IU or serum 25-hydroxyvitamin D concentrations than 60 nmol/L may not reduce the risk of falling among older individuals (45).
Non-skeletal actions of vitamin D

Figure 3. Evaluation of the Strength of Hip Flexors (SFH) after six-month vitamin D replacement in institutionalized elderly. (A) Shows the significant increment in SFH observed in the group that received vitamin D treatment (average of 3600 UI/day), which was not seen in the placebo group. (B) Demonstrates that the SFH increment was seen only in those who had lower levels of 25OHD levels at baseline (< 50 nmol/L) (43).

Cardiovascular disease

Recent evidence suggests that vitamin D may play a role in mortality risk. The major circulating form of vitamin D, 25OHD, has been associated with all causes of mortality in individuals with end-stage renal disease and coronary artery disease and even in the general population (46). Further evidence suggests that vitamin D supplementation may lower mortality. Several mechanisms can be considered in the relationship between vitamin D and cardiovascular disease (CVD). The first is the effect on the renin-angiotensin system (RAS) (47). As vitamin D inhibits renin activity, vitamin D deficiency activates RAS. Vitamin D also has protective effects on CVD by suppressing cardiac hypertrophy. As inflammation is involved in atherosclerosis, which is CVD’s basic clinical condition, vitamin D possibly suppresses CVD events through its anti-inflammatory function. This indicates that vitamin D is influential in the inhibition of CVD events from different pathways (48).

Psychiatric and neurologic disorders

Vitamin D deficiency is common in older adults and has been implicated with psychiatric and neurological disorders such as depression, multiple sclerosis, fibromyalgia, schizophrenia and Parkinson’s disease. Depression has incidentally been related to altered levels of 25OHD, but this relation has never been studied systematically. Murphy and Wagner (49) evaluated, in an integrative review, studies that investigated the association between vitamin D and mood disorders in women. The authors found a significant association between mood disorders and low 25OHD levels in four of six studies, indicating that some biochemical mechanism may exist between these two variables. In a cross-sectional study to investigate the relationship among vitamin D status and cognitive performance, mood and physical performance in older adults, the authors showed that vitamin D deficiency was associated with low mood and impairment in two of four evaluations of cognitive performance (50). A large prospective study found that high circulating levels of vitamin D were associated with a lower risk of multiple sclerosis (51). Besides that, a large population-based cohort study demonstrated an association between depression status and severity with decreased circulating levels of 25OHD and increased serum PTH levels in older individuals (52). These associations warrant further studies to confirm the influence of vitamin status on psychiatric and neurological disorders.

Microbial infections

The innate immunity plays a critical role in human defense. The innate immune response includes recogni-
tion of microbial invasion and production of antimicrobial peptides such as defensins and cathelicidins (10). The discovery of VDR expression in activated inflammatory cells signalized the importance of vitamin D and the active form 1,25(OH)_2D_3 in the immune function (53). Exposing monocytes and macrophages to 1,25(OH)_2D_3 improves their chemotactic and phagocytic capacities, features that are indispensable for their tumor cell cytotoxicity and microbacterial activity (10). The current vitamin D-dependent antimicrobial immunity model proposes that when a pathogen is detected by its respective Toll-like receptor (pattern-recognition receptor), VDR and 1α-hydroxylase gene expression are induced (10,53). This leads to 1α-hydroxylation of 25OHD, which is taken up from the blood, and subsequent binding of 1,25(OH)_2D_3 to the VDR. The cathelicidin gene is activated and its respective protein is synthesized for use against the pathogen that has been engulfed in the phagosome of the macrophage (53).

Elevated 1,25(OH)_2D_3 and hypercalcaemia have been associated with active pulmonary tuberculosis, and epidemiological studies have demonstrated that lower serum concentration of 25OHD correlates with increased susceptibility to tuberculosis (54). The beneficial effects of vitamin D supplementation on treatment of tuberculosis have been studied in randomized clinical trials, but conflicting results have been reported (53). Further clinical trials are needed to elucidate the potential therapeutic applications of vitamin D and its synthetic analogs against tuberculosis and other infectious diseases (53).

CONCLUSION
In the last twenty years, vitamin D and its non-classical actions have taken an important place in the clinical scenario. After this discovery, many epidemiological and interventional studies have proved the benefits of vitamin D sufficiency status in promoting good health. The search for vitamin D synthetic analogs without calcemic activity will allow the promising clinical use of these hormone analogs in the prevention and treatment of chronic diseases, like cancer, diabetes, muscle weakness and autoimmune diseases.

Acknowledgment: Marise Lazaretti-Castro is a consultant at Sanofi-Aventis and Novartis and participates as Principal Investigator in clinical research trials supported by Merck, Sharp & Dohme, Eli Lilly and Pfizer. Patricia Muszekat participates as sub-investigator in clinical research trials supported by Merck, Sharp & Dohme, Eli Lilly and Pfizer.

Disclosure: no potential conflict of interest relevant to this article was reported.

REFERENCES


